Request an Appointment



Contact us with Questions

Expand Content

Robert Dreicer, MD


Robert Dreicer, MD
Department: Hematology and Oncology
Location: Cleveland Clinic Main Campus
Mail Code R35
9500 Euclid Avenue
Cleveland, OH 44195
Robert Dreicer, MD
Department: Urology
Location: Cleveland Clinic Main Campus
Mail Code R35
9500 Euclid Avenue
Cleveland, OH 44195
Adults Only

Biographical Sketch

Robert Dreicer, MD, M.S., FACP, is Chairman of the Department of Solid Tumor Oncology at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Dreicer is board-certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology.  Dr. Dreicer received his B.S. degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas.  He received his medical degree from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He joined the Division of Hematology/Oncology at the University of Iowa in 1989 and upon his departure, he was a tenured Associate Professor of Medicine and Associate Division Director of Hematology/Oncology. Dr. Dreicer was appointed as a Staff Physician in Hematology/Oncology with a secondary appointment in the Urologic Institute. He was appointed Director of the Genitourinary Medical Oncology program and Associate Director of the Experimental Therapeutics Program in 2000 and Chairman of the Department of Solid Tumor Oncology in January of 2006. Dr. Dreicer has published widely in genitourinary oncology, and is the principle investigator of a large number of ongoing studies in genitourinary neoplasms.  He is the Chair of the Bladder Subcommittee of the Eastern Cooperative Oncology Group and a Fellow of the American College of Physicians. He was Chair of the Steering Committee for ASCO's 2008 GU Oncology Meeting. He is, an Associate Editor of Urology, and a member of the editorial boards of the Journal of Clinical Oncology, the New England Journal of Medicine's Journal Watch Hematology/Oncology and The Journal Of Supportive Oncology.  He is a member of the scientific advisory board of Transgene.

Professional Highlights

  • Associate Editor, Urology
  • Co-Chair NCI GU Steering Committee
  • Member ABIM medical oncology panel
  • Editorial Board, Journal of Clinical Oncology
  • Editorial Board, Journal of Supportive Oncology
  • Associate Editor, New England Journal of Medicine, Journal Watch Hematology/Oncology

Education & Fellowships

Fellowship - University of Wisconsin Hospital and Clinic
Medical Oncology
Madison, WI USA
Residency - Indiana University Medical Center
Internal Medicine
Indianapolis, IN USA
Internship - Indiana University Medical Center
Internal Medicine
Indianapolis, IN USA
Medical School - University of Texas, Houston
Houston, TX USA
Graduate - University of Texas, Houston
Houston, TX USA
Undergraduate - Colorado State University
Fort Collins, CO USA


  • Internal Medicine
  • Internal Medicine- Medical Oncology

Specialty Interests

Adrenal cancer, bladder cancer, kidney cancer, penile cancer, prostate cancer, renal pelvis cancer, testicular cancer, urethral cancer, experimental therapeutics, cancer

Awards & Honors

  • Fellow of the American College of Physicians
  • America's Top  Doctors For Cancer  2005-2011 (Castle Connolly Ltd. Peer Nomination)
  • American Society of Clinical Oncology Statesman's award  2011

Additional Training

Master of Science, University of Texas Graduate School of Biomedical Sciences-Houston


  • American Society of Clinical Oncology
  • Society of Urologic Oncology
  • American Urologic Association
  • American College of Physicians

Treatment & Services

  • Chemotherapy
  • Clinical Trials
  • Experimental Therapeutics
  • Medical Oncology

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/3/2014, Dr. Dreicer has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Dreicer receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Bayer Healthcare Pharmaceuticals, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English